Tesaro
Public | |
Industry | Pharmaceuticals |
Founded | 2010 in Waltham, Massachusetts |
Products | Varubi |
Number of employees | 286 (2016) |
Website |
www |
Tesaro is a public pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer.
History
Tesaro was founded in 2010.[1] The company's first commercial product, Varubi, was approved by the FDA in October 2015.[2] As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD.[3] The company's product Nirabarib was granted priority review and was given a target action date of June 2017 by the FDA.[4] In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer.[5] On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale.[5]
Products under development
- Rolapitant – intravenous form in phase III clinical trials for use in chemotherapy-induced nausea and vomiting
- Niraparib – PARP inhibitor in clinical trials for breast and ovarian cancer.[6]
- TSR-042
- TSR-022
References
- ↑ "Tesaro". FierceBiotech. Retrieved 2017-02-25.
- ↑ "TESARO - Quarterly Report". Ir.tesarobio.com. Retrieved 2017-02-25.
- ↑ "TESARO - Annual Report". Ir.tesarobio.com. Retrieved 2017-02-25.
- ↑ ESARO (TSRO) Announces Priority FDA Review for Niraparib NDA, Street Insider, December 20, 2016, retrieved June 8, 2017
- 1 2 D. Rockoff, Jonathan; Cimilluca, Dana (May 31, 2017). "Tesaro Explores Sale". Wall Street Journal. New York City, New York. Retrieved June 1, 2017.
- ↑ "2016 Press Release: Niraparib Significantly Improves Outcome of Ovarian Cancer Patients in Landmark Trial". ESMO. Retrieved 2017-02-25.
External links
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.